We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add DexCom Stock to Your Portfolio Now
Read MoreHide Full Article
Key Takeaways
DexCom is poised for growth on strong CGM demand, solid Q4 performance and favorable coverage decisions.
DXCM sees expansion via type 2 non-insulin patients and G7 platform boosting adoption and margins.
DexCom's international growth and reimbursement gains drive momentum, despite pricing and margin risks.
DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. Risks related to stiff competition persist.
This Zacks Rank #2 (Buy) company’s shares have lost 7.3% so far this year compared with the industry’s 11.6% decline. The S&P 500 Index has gained 1.9% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $24.23 billion. It projects a 20.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed in one, the average surprise being 3.82%.
Let’s delve deeper.
Positive Drivers
Expanding Addressable Market: DexCom’s long-term growth trajectory is anchored in a significant expansion of its addressable market, particularly among type 2 non-insulin patients. Management highlighted that Medicare coverage for this population could unlock access for nearly 12 million additional patients, with private payer coverage already progressing.
Clinical evidence, registry data and upcoming randomized trial readouts further support adoption in this segment. Given strong utilization trends among early adopters, this expansion represents a structural demand driver that could sustain double-digit growth for multiple years.
G7 15-Day Platform Enhances Product Differentiation: The rollout of the G7 15-day sensor represents a meaningful innovation cycle, improving wear duration, accuracy and patient convenience. Early feedback from physicians and users has been highly positive, reinforcing DexCom’s positioning as a premium CGM provider.
The platform also supports margin expansion through lower per-day manufacturing costs and supply-chain efficiencies. Over time, as the installed base transitions to this platform globally, the company expects both improved customer retention and stronger gross margins, creating a dual benefit of growth and profitability.
Strong International Growth With Long-Term Upside Potential: DexCom’s international business grew 18% reportedly (15% organic) in the fourth quarter, outperforming the U.S. market and demonstrating strong momentum in markets such as Germany, France and the United Kingdom.
Expanded reimbursement, particularly for type 2 patients in Europe, is accelerating adoption. Management emphasized that international markets could eventually surpass the United States in size, given lower current penetration and significant untapped demand. Continued expansion into new geographies, combined with a tiered product portfolio strategy, positions DexCom for sustained global share gains over the long term.
Risks
Pricing Pressure and Volume-Price Trade-Off: As DexCom expands access, particularly in the type 2 non-insulin segment, it faces inherent pricing pressure from payers. Management acknowledged ongoing volume-price trade-offs during annual negotiations, with pricing largely stable but constrained.
While increased patient volumes can offset pricing pressure, broader reimbursement, especially under Medicare, could introduce further pricing compression through competitive bidding mechanisms. This dynamic creates a structural challenge where long-term growth is increasingly volume-driven, potentially limiting average selling price expansion and moderating revenue growth quality.
Margin Volatility From Ireland Manufacturing Ramp-Up: DexCom’s planned Ireland manufacturing facility introduces near-term cost headwinds, as operating expenses related to staffing, validation and depreciation will be incurred before full production ramp.
Management expects these costs to temporarily weigh on margins, particularly as fixed overhead shifts into cost of goods sold in late 2026. While the facility enhances long-term capacity and efficiency, the transitional phase creates margin volatility and execution risk, especially if ramp timelines or utilization levels fall short of expectations.
DexCom has witnessed a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $2.49.
The consensus mark for the company’s first-quarter revenues is pegged at $1.18 billion, indicating a 13.6% improvement from the year-ago quarter’s reported number. The consensus estimate for first-quarter earnings is pinned at 47 cents per share, implying an improvement of 46.9% year over year.
Other Stocks to Consider
Some other top-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently flaunting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $45 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings decline rate of 1.9% against the industry’s 11.4% growth. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.7%.
Globus Medical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $1.28, which outpaced the Zacks Consensus Estimate by 20.8%. Revenues of $826 million surpassed the Zacks Consensus Estimate by 4.9%.
GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 14% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 13.2%.
Biodesix, currently carrying a Zacks Rank of 2, reported a fourth-quarter 2025 adjusted loss per share of 49 cents, which beat the Zacks Consensus Estimate by 53.33%. Revenues of $29 million beat the Zacks Consensus Estimate by 14.1%.
BDSX has an estimated earnings growth rate of 22.5% for 2026 compared with the industry’s 12% rise. The company beat earnings estimates in two of the trailing four quarters, missed in one and met in the other, with the average surprise being 16.64%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Add DexCom Stock to Your Portfolio Now
Key Takeaways
DexCom, Inc. (DXCM - Free Report) is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong fourth-quarter 2025 performance and a series of favorable coverage decisions are expected to contribute further. Risks related to stiff competition persist.
This Zacks Rank #2 (Buy) company’s shares have lost 7.3% so far this year compared with the industry’s 11.6% decline. The S&P 500 Index has gained 1.9% in the same time frame.
DXCM, a renowned medical device company and provider of continuous glucose monitoring (CGM) systems, has a market capitalization of $24.23 billion. It projects a 20.6% growth rate over the next five years and anticipates maintaining a strong performance going forward.
Image Source: Zacks Investment Research
DexCom’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed in one, the average surprise being 3.82%.
Let’s delve deeper.
Positive Drivers
Expanding Addressable Market: DexCom’s long-term growth trajectory is anchored in a significant expansion of its addressable market, particularly among type 2 non-insulin patients. Management highlighted that Medicare coverage for this population could unlock access for nearly 12 million additional patients, with private payer coverage already progressing.
Clinical evidence, registry data and upcoming randomized trial readouts further support adoption in this segment. Given strong utilization trends among early adopters, this expansion represents a structural demand driver that could sustain double-digit growth for multiple years.
G7 15-Day Platform Enhances Product Differentiation: The rollout of the G7 15-day sensor represents a meaningful innovation cycle, improving wear duration, accuracy and patient convenience. Early feedback from physicians and users has been highly positive, reinforcing DexCom’s positioning as a premium CGM provider.
The platform also supports margin expansion through lower per-day manufacturing costs and supply-chain efficiencies. Over time, as the installed base transitions to this platform globally, the company expects both improved customer retention and stronger gross margins, creating a dual benefit of growth and profitability.
Strong International Growth With Long-Term Upside Potential: DexCom’s international business grew 18% reportedly (15% organic) in the fourth quarter, outperforming the U.S. market and demonstrating strong momentum in markets such as Germany, France and the United Kingdom.
Expanded reimbursement, particularly for type 2 patients in Europe, is accelerating adoption. Management emphasized that international markets could eventually surpass the United States in size, given lower current penetration and significant untapped demand. Continued expansion into new geographies, combined with a tiered product portfolio strategy, positions DexCom for sustained global share gains over the long term.
Risks
Pricing Pressure and Volume-Price Trade-Off: As DexCom expands access, particularly in the type 2 non-insulin segment, it faces inherent pricing pressure from payers. Management acknowledged ongoing volume-price trade-offs during annual negotiations, with pricing largely stable but constrained.
While increased patient volumes can offset pricing pressure, broader reimbursement, especially under Medicare, could introduce further pricing compression through competitive bidding mechanisms. This dynamic creates a structural challenge where long-term growth is increasingly volume-driven, potentially limiting average selling price expansion and moderating revenue growth quality.
Margin Volatility From Ireland Manufacturing Ramp-Up: DexCom’s planned Ireland manufacturing facility introduces near-term cost headwinds, as operating expenses related to staffing, validation and depreciation will be incurred before full production ramp.
Management expects these costs to temporarily weigh on margins, particularly as fixed overhead shifts into cost of goods sold in late 2026. While the facility enhances long-term capacity and efficiency, the transitional phase creates margin volatility and execution risk, especially if ramp timelines or utilization levels fall short of expectations.
DexCom, Inc. Price
DexCom, Inc. price | DexCom, Inc. Quote
Estimate Trend
DexCom has witnessed a stable estimate revision trend for 2026. In the past 30 days, the Zacks Consensus Estimate for 2026 earnings per share has remained unchanged at $2.49.
The consensus mark for the company’s first-quarter revenues is pegged at $1.18 billion, indicating a 13.6% improvement from the year-ago quarter’s reported number. The consensus estimate for first-quarter earnings is pinned at 47 cents per share, implying an improvement of 46.9% year over year.
Other Stocks to Consider
Some other top-ranked stocks from the same medical industry are Pacific Biosciences of California (PACB - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .
Pacific Biosciences of California, currently flaunting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss per share of 12 cents, which surpassed the Zacks Consensus Estimate by 36.8%. Revenues of $45 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
PACB has an estimated earnings decline rate of 1.9% against the industry’s 11.4% growth. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 27.7%.
Globus Medical, carrying a Zacks Rank #2 at present, reported fourth-quarter 2025 adjusted EPS of $1.28, which outpaced the Zacks Consensus Estimate by 20.8%. Revenues of $826 million surpassed the Zacks Consensus Estimate by 4.9%.
GMED has an estimated long-term earnings growth rate of 9.6% compared with the industry’s 14% rise. The company beat earnings estimates in each of the trailing four quarters, with the average surprise being 13.2%.
Biodesix, currently carrying a Zacks Rank of 2, reported a fourth-quarter 2025 adjusted loss per share of 49 cents, which beat the Zacks Consensus Estimate by 53.33%. Revenues of $29 million beat the Zacks Consensus Estimate by 14.1%.
BDSX has an estimated earnings growth rate of 22.5% for 2026 compared with the industry’s 12% rise. The company beat earnings estimates in two of the trailing four quarters, missed in one and met in the other, with the average surprise being 16.64%.